Submit a Revision

*your email :**
page name* : such as "Introduction", "Conclusion"..etc
<ol><li> <p> <a></a>Mansky LM, Temin HM: <strong>Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. </strong> </p> <p> <em>Journal of Virology</em> 1995, <strong>69</strong><strong>:</strong>5087-5094. </p> <p> </p> </li> <li> <p> <a></a>Levy DN, Aldrovandi GM, Kutsch O, Shaw GM: <strong>Dynamics of HIV-1 recombination in its natural target cells. </strong> </p> <p> <em>Proc Natl Acad Sci U S A</em> 2004, <strong>101</strong>(12)<strong>:</strong>4204-4209. </p> <p> </p> </li> <li> <p> <a></a>Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: <strong>HIV-1 dynamics in vivo: virion clearance rate, infected cell lifetime, and viral generation time. </strong> </p> <p> <em>Science</em> 1996, <strong>271</strong><strong>:</strong>1582-1586. </p> <p> </p> </li> <li> <p> <a></a>Bourinbaiar AS: <strong>The ratio of defective HIV-1 particles to replication-competent infectious virions. </strong> </p> <p> <em>Acta Virol</em> 1994, <strong>38</strong>(1)<strong>:</strong>59-61. </p> <p> </p> </li> <li> <p> <a></a>Li Y, Hui H, Burgess CJ, Price RW, Sharp PM, Hahn BH, Shaw GM: <strong>Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. </strong> </p> <p> <em>Journal of Virology</em> 1992, <strong>66</strong><strong>:</strong>6587-6600. </p> <p> </p> </li> <li> <p> <a></a>Sanchez G, Xu X, Chermann JC, Hirsch I: <strong>Accumulation of defective viral genomes in peripheral blood mononuclear cells fo HIV infected individuals. </strong> </p> <p> <em>Journal of Virology</em> 1997, <strong>71</strong><strong>:</strong>2233-2240. </p> <p> </p> </li> <li> <p> <a></a>Eigen M: <strong>Selforganization of matter and the evolution of biological macromolecules. </strong> </p> <p> <em>Naturwissenschaften</em> 1971, <strong>58</strong>(10)<strong>:</strong>465-523. </p> <p> </p> </li> <li> <p> <a></a>Eigen M: <strong>Error catastrophe and antiviral strategy. </strong> </p> <p> <em>Proc Natl Acad Sci U S A</em> 2002, <strong>99</strong>(21)<strong>:</strong>13374-13376. </p> <p> </p> </li> <li> <p> <a></a>Loeb LA, Essigmann JM, Kazazi F, Zhang J, Rose KD, Mullins JI: <strong>Lethal mutagenesis of HIV with mutagenic nucleoside analogs. </strong> </p> <p> <em>Proc Natl Acad Sci U S A</em> 1999, <strong>96</strong>(4)<strong>:</strong>1492-1497. </p> <p> </p> </li> <li> <p> <a></a>Smith RA, Loeb LA, Preston BD: <strong>Lethal mutagenesis of HIV. </strong> </p> <p> <em>Virus Res</em> 2005, <strong>107</strong>(2)<strong>:</strong>215-228. </p> <p> </p> </li> <li> <p> <a></a>Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE: <strong>The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. </strong> </p> <p> <em>Nat Med</em> 2000, <strong>6</strong>(12)<strong>:</strong>1375-1379. </p> <p> </p> </li> <li> <p> <a></a>Lau JY, Tam RC, Liang TJ, Hong Z: <strong>Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. </strong> </p> <p> <em>Hepatology</em> 2002, <strong>35</strong>(5)<strong>:</strong>1002-1009. </p> <p> </p> </li> <li> <p> <a></a>Lecossier D, Bouchonnet F, Clavel F, Hance AJ: <strong>Hypermutation of HIV-1 DNA in the absence of the Vif protein. </strong> </p> <p> <em>Science</em> 2003, <strong>300</strong>(5622)<strong>:</strong>1112. </p> <p> </p> </li> <li> <p> <a></a>Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM: <strong>Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. </strong> </p> <p> <em>J Virol</em> 2004, <strong>78</strong>(11)<strong>:</strong>6073-6076. </p> <p> </p> </li> <li> <p> <a></a>Sheehy AM, Gaddis NC, Choi JD, Malim MH: <strong>Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. </strong> </p> <p> <em>Nature</em> 2002, <strong>418</strong>(6898)<strong>:</strong>646-650. </p> <p> </p> </li> <li> <p> <a></a>Sheehy AM, Gaddis NC, Malim MH: <strong>The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. </strong> </p> <p> <em>Nat Med</em> 2003, <strong>9</strong>(11)<strong>:</strong>1404-1407. </p> <p> </p> </li> <li> <p> <a></a>Stopak K, de Noronha C, Yonemoto W, Greene WC: <strong>HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. </strong> </p> <p> <em>Mol Cell</em> 2003, <strong>12</strong>(3)<strong>:</strong>591-601. </p> <p> </p> </li> <li> <p> <a></a>Mezei M, Minarovits J: <strong>Reversal of HIV drug resistance and novel strategies to curb HIV infection: the viral infectivity factor Vif as a target and tool of therapy. </strong> </p> <p> <em>Curr Drug Targets</em> 2006, <strong>7</strong>(7)<strong>:</strong>881-885. </p> <p> </p> </li> <li> <p> <a></a>Carr JM, Davis AJ, Feng F, Burrell CJ, Li P: <strong>Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more? </strong> </p> <p> <em>Curr Drug Targets</em> 2006, <strong>7</strong>(12)<strong>:</strong>1583-1593. </p> <p> </p> </li> <li> <p> <a></a>Stopak K, Greene WC: <strong>Protecting APOBEC3G: a potential new target for HIV drug discovery. </strong> </p> <p> <em>Curr Opin Investig Drugs</em> 2005, <strong>6</strong>(2)<strong>:</strong>141-147. </p> <p> </p> </li> <li> <p> <a></a>Fessel J: <strong>A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem. </strong> </p> <p> <em>Med Hypotheses</em> 2005, <strong>64</strong>(2)<strong>:</strong>261-263. </p> <p> </p> </li> <li> <p> <a></a>Hirsch MS: <strong>HIV drug resistance--a chink in the armor. </strong> </p> <p> <em>N Engl J Med</em> 2002, <strong>347</strong>(6)<strong>:</strong>438-439. </p> <p> </p> </li> <li> <p> <a></a>Suspene R, Sommer P, Henry M, Ferris S, Guetard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP: <strong>APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. </strong> </p> <p> <em>Nucleic Acids Res</em> 2004, <strong>32</strong>(8)<strong>:</strong>2421-2429. </p> <p> </p> </li> <li> <p> <a></a>Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S: <strong>Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. </strong> </p> <p> <em>Nucleic Acids Res</em> 2006, <strong>34</strong>(17)<strong>:</strong>4677-4684. </p> <p> </p> </li> <li> <p> <a></a>Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR: <strong>Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. </strong> </p> <p> <em>Nat Struct Mol Biol</em> 2004, <strong>11</strong>(5)<strong>:</strong>435-442. </p> <p> </p> </li> <li> <p> <a></a>Xu H, Chertova E, Chen J, Ott DE, Roser JD, Hu WS, Pathak VK: <strong>Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. </strong> </p> <p> <em>Virology</em> 2007, <strong>360</strong>(2)<strong>:</strong>247-256. </p> <p> </p> </li> <li> <p> <a></a>Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, Kao S, Strebel K: <strong>Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. </strong> </p> <p> <em>Retrovirology</em> 2007, <strong>4</strong><strong>:</strong>48. </p> <p> </p> </li> <li> <p> <a></a>Chen KM, Martemyanova N, Lu Y, Shindo K, Matsuo H, Harris RS: <strong>Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. </strong> </p> <p> <em>FEBS Lett</em> 2007, <strong>581</strong>(24)<strong>:</strong>4761-4766. </p> <p> </p> </li> <li> <p> <a></a>Opi S, Takeuchi H, Kao S, Khan MA, Miyagi E, Goila-Gaur R, Iwatani Y, Levin JG, Strebel K: <strong>Monomeric APOBEC3G is catalytically active and has antiviral activity. </strong> </p> <p> <em>J Virol</em> 2006, <strong>80</strong>(10)<strong>:</strong>4673-4682. </p> <p> </p> </li> <li> <p> <a></a>Mansky LM, Pearl DK, Gajary LC: <strong>Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies. </strong> </p> <p> <em>J Virol</em> 2002, <strong>76</strong>(18)<strong>:</strong>9253-9259. </p> <p> </p> </li> <li> <p> <a></a>Summers J, Litwin S: <strong>Examining the theory of error catastrophe. </strong> </p> <p> <em>J Virol</em> 2006, <strong>80</strong>(1)<strong>:</strong>20-26. </p> <p> </p> </li> <li> <p> <a></a>Bull JJ, Sanjuan R, Wilke CO: <strong>Theory of lethal mutagenesis for viruses. </strong> </p> <p> <em>J Virol</em> 2007, <strong>81</strong>(6)<strong>:</strong>2930-2939. </p> <p> </p> </li> <li> <p> <a></a>Berkhout B, de Ronde A: <strong>APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. </strong> </p> <p> <em>Aids</em> 2004, <strong>18</strong>(13)<strong>:</strong>1861-1863. </p> <p> </p> </li> <li> <p> <a></a>Liddament MT, Brown WL, Schumacher AJ, Harris RS: <strong>APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. </strong> </p> <p> <em>Curr Biol</em> 2004, <strong>14</strong>(15)<strong>:</strong>1385-1391. </p> <p> </p> </li> <li> <p> <a></a>Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD: <strong>Update of the drug resistance mutations in HIV-1: Fall 2006. </strong> </p> <p> <em>Top HIV Med</em> 2006, <strong>14</strong>(3)<strong>:</strong>125-130. </p> <p> </p> </li> <li> <p> <a></a>Carvajal-Rodriguez A, Crandall KA, Posada D: <strong>Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy. </strong> </p> <p> <em>Infect Genet Evol</em> 2007, <strong>7</strong>(4)<strong>:</strong>476-483. </p> <p> </p> </li> <li> <p> <a></a>Moutouh L, Corbeil J, Richman DD: <strong>Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. </strong> </p> <p> <em>Proc Natl Acad Sci USA</em> 1996, <strong>93</strong><strong>:</strong>6106-6111. </p> <p> </p> </li> <li> <p> <a></a>Kellam P, Larder BA: <strong>Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. </strong> </p> <p> <em>Journal of Virology</em> 1995, <strong>69</strong><strong>:</strong>669-674. </p> <p> </p> </li> <li> <p> <a></a>Yuste E, Sanchez-Palomino S, Casado C, Domingo E, Lopez-Galindez C: <strong>Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. </strong> </p> <p> <em>J Virol</em> 1999, <strong>73</strong>(4)<strong>:</strong>2745-2751. </p> <p> </p> </li> <li> <p> <a></a><strong>Los Alamos National Lab HIV Sequence Database </strong>[<a href="http://www.hiv.lanl.gov/">http://www.hiv.lanl.gov</a>] </p> <p> </p> </li> <li> <p> <a></a>Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S: <strong>Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. </strong> </p> <p> <em>J Virol</em> 2006, <strong>80</strong>(18)<strong>:</strong>9259-9269. </p> <p> </p> </li> <li> <p> <a></a>Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD: <strong>Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. </strong> </p> <p> <em>PLoS Pathog</em> 2005, <strong>1</strong>(1)<strong>:</strong>e6. </p> <p> </p> </li> <li> <p> <a></a>Cho SJ, Drechsler H, Burke RC, Arens MQ, Powderly W, Davidson NO: <strong>APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. </strong> </p> <p> <em>J Virol</em> 2006, <strong>80</strong>(4)<strong>:</strong>2069-2072. </p> <p> </p> </li> <li> <p> <a></a>Jin X, Wu H, Smith H: <strong>APOBEC3G levels predict rates of progression to AIDS. </strong> </p> <p> <em>Retrovirology</em> 2007, <strong>4</strong><strong>:</strong>20. </p> <p> </p> </li> <li> <p> <a></a>An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, O'Brien SJ, Telenti A, Winkler CA: <strong>APOBEC3G genetic variants and their influence on the progression to AIDS. </strong> </p> <p> <em>J Virol</em> 2004, <strong>78</strong>(20)<strong>:</strong>11070-11076. </p> <p> </p> </li> <li> <p> <a></a>Desrosiers RC: <strong>Prospects for an AIDS vaccine. </strong> </p> <p> <em>Nat Med</em> 2004, <strong>10</strong>(3)<strong>:</strong>221-223. </p> <p> </p> </li> <li> <p> <a></a>Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC: <strong>Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. </strong> </p> <p> <em>Nature</em> 2005, <strong>435</strong>(7038)<strong>:</strong>108-114. </p> <p> </p> </li> <li> <p> <a></a>Bishop KN, Holmes RK, Malim MH: <strong>Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination. </strong> </p> <p> <em>J Virol</em> 2006, <strong>80</strong>(17)<strong>:</strong>8450-8458. </p> <p> </p> </li> <li> <p> <a></a>Soros VB, Yonemoto W, Greene WC: <strong>Newly Synthesized APOBEC3G Is Incorporated into HIV Virions, Inhibited by HIV RNA, and Subsequently Activated by RNase H. </strong> </p> <p> <em>PLoS Pathog</em> 2007, <strong>3</strong>(2)<strong>:</strong>e15. </p> <p> </p> </li> <li> <p> <a></a>Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K: <strong>Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. </strong> </p> <p> <em>J Virol</em> 2007, <strong>81</strong>(24)<strong>:</strong>13346-13353. </p> <p> </p> </li> <li> <p> <a></a><strong>Stanford HIV Drug Resistance Database </strong>[<a href="http://hivdb.stanford.edu/">http://hivdb.stanford.edu/</a>] </p> <p> </p> </li> </ol>
Confirmation code: Enter the code exactly as it appears. All letters are case insensitive, there is no zero.